{"id":402,"date":"2022-03-08T13:05:02","date_gmt":"2022-03-08T13:05:02","guid":{"rendered":"https:\/\/hcrplatform.com\/?page_id=402"},"modified":"2023-06-29T20:05:43","modified_gmt":"2023-06-29T20:05:43","slug":"%e1%83%99%e1%83%9a%e1%83%98%e1%83%9c%e1%83%98%e1%83%99%e1%83%a3%e1%83%a0%e1%83%98-%e1%83%99%e1%83%95%e1%83%9a%e1%83%94%e1%83%95%e1%83%94%e1%83%91%e1%83%98","status":"publish","type":"page","link":"https:\/\/hcrplatform.com\/?page_id=402&lang=ka","title":{"rendered":"\u10d9\u10da\u10d8\u10dc\u10d8\u10d9\u10e3\u10e0\u10d8 \u10d9\u10d5\u10da\u10d4\u10d5\u10d4\u10d1\u10d8"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n
\n

\u10de\u10da\u10d0\u10e2\u10e4\u10dd\u10e0\u10db\u10d8\u10e1 \u10ec\u10d4\u10d5\u10e0\u10d4\u10d1\u10d8 \u10db\u10dd\u10dc\u10d0\u10ec\u10d8\u10da\u10d4\u10dd\u10d1\u10d0\u10e1 \u10d8\u10e6\u10d4\u10d1\u10d4\u10dc \u10db\u10d8\u10db\u10d3\u10d8\u10dc\u10d0\u10e0\u10d4 \u10e1\u10d0\u10d4\u10e0\u10d7\u10d0\u10e8\u10dd\u10e0\u10d8\u10e1\u10dd \u10d9\u10d5\u10da\u10d4\u10d5\u10d4\u10d1\u10e8\u10d8:<\/h2>\n<\/div>\n<\/div>\n
\n
\n
    \n \t
  1. Clinical Evaluation of the\u00a0<\/strong>Panbio\u2122<\/strong>COVID-19<\/strong>\/ Flu A&B Rapid Panel.<\/strong>\u00a0.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sponsor: Abbott Rapid Diagnostics Jena GmbH, Start: 01.11.2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Kakha Nadaraia \u2013 Principal Investigator (PI)<\/strong><\/li>\n<\/ol>\n\u00a0<\/strong>\n
      \n \t
    1. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study\u00a0to Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (AMUC2023)<\/strong><\/li>\n<\/ol>\nSPONSOR: Bausch Health Americas, Inc.\u00a0 Start: 09.2021\n\nKakha Nadaraia \u2013 Subinvestigator\u00a0<\/strong>\n\n\u00a0<\/strong>\n
        \n \t
      1. Alfapump\u00ae DSR Feasibility Study in Subjects with Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic Treatment (SAHARA)<\/strong><\/li>\n<\/ol>\nSponsor: Sequana Medical N.V.\u00a0\u00a0\u00a0 Start: 05.2021\n\nZurab Klimiashvili \u2013 Principal Investigator (PI), Tamar Shengelia \u2013 Study Coordinator<\/strong>\n\n \n
          \n \t
        1. A Randomized, Placebo-Controlled, Double-blind 52 week Study\u00a0to Assess the Efficacy and safety of etrazimod in subjects With Moderately active Ulcerative Colitis<\/strong><\/li>\n<\/ol>\nSponsor:\u00a0<\/strong>Arena Pharmaceuticals,\u00a0 Start: 19.04.2021\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n \n
            \n \t
          1. A Multicenter, Randomized, Double-Blind, Parallel-Group Study\u00a0to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn\u2019s Disease<\/strong>\u00a0(CULTIVATE),<\/strong><\/li>\n<\/ol>\nSponsor:\u00a0<\/strong>Arena Pharmaceuticals, Start: 12.02.2020\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n \n
              \n \t
            1. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel-Group Study of\u00a0Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (Raasi) Medications for the Treatment of Heart Failure (DIAMOND)<\/strong><\/li>\n<\/ol>\nSponsor:\u00a0\u00a0<\/strong>Vifor Pharma, Inc.\u00a0Collaborator:\u00a0<\/strong>Syneos Health, LLC, Start: 25.04.2019\n\nKakha Nadaraia \u2013 Study Coordinator and Subinvestigator<\/strong>\n\n \n
                \n \t
              1. Induction Study #1 \u2013 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of\u00a0Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn\u2019s Disease<\/strong><\/li>\n<\/ol>\nSponsor: Celgene,\u00a0\u00a0 Start: 27.02.2018\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n \n
                  \n \t
                1. Induction Study #2 \u2013 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of\u00a0Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn\u2019s Disease<\/strong><\/li>\n<\/ol>\nSponsor: Celgene,\u00a0\u00a0 Start: 07.03.2018\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n \n
                    \n \t
                  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of\u00a0Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn\u2019s Disease<\/strong><\/li>\n<\/ol>\nSponsor: Celgene,\u00a0\u00a0 Start: 27.06.2018\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n \n
                      \n \t
                    1. A Phase 3, Multicenter, Open-Label Extension Study of\u00a0Oral Ozanimod for Moderately to Severely Active Crohn\u2019s Disease<\/strong><\/li>\n<\/ol>\nSponsor: Celgene, Start: 22.08.2018\n\nKakha Nadaraia \u2013 Subinvestigator<\/strong>\n\n\u00a0<\/strong>\n
                        \n \t
                      1. A Randomized, Double-Blind, Placebo-Controlled\u00a0Study to Investigate the Efficacy and Safety of Injectafer\u00ae (Ferric\u00a0 Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency\u00a0(HEART-FID)<\/strong><\/li>\n<\/ol>\nSponsor: American Regents inc.\u00a0 Start: 03.2017\n\nZurab Klimiashvili \u2013 Principal Investigator (PI)<\/strong>\n\n\u00a0<\/strong>\n
                          \n \t
                        1. A Phase 3, Multicenter, Open-Label Extension Trial of\u00a0Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis<\/strong><\/li>\n<\/ol>\nSponsor: Celgene,\u00a0 Start: 02.12. 2015\n\nKakha Nadaraia \u2013 Cardiologist<\/strong>\n\n<\/div>\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

                          \u10de\u10da\u10d0\u10e2\u10e4\u10dd\u10e0\u10db\u10d8\u10e1 \u10ec\u10d4\u10d5\u10e0\u10d4\u10d1\u10d8 \u10db\u10dd\u10dc\u10d0\u10ec\u10d8\u10da\u10d4\u10dd\u10d1\u10d0\u10e1 \u10d8\u10e6\u10d4\u10d1\u10d4\u10dc \u10db\u10d8\u10db\u10d3\u10d8\u10dc\u10d0\u10e0\u10d4 \u10e1\u10d0\u10d4\u10e0\u10d7\u10d0\u10e8\u10dd\u10e0\u10d8\u10e1\u10dd \u10d9\u10d5\u10da\u10d4\u10d5\u10d4\u10d1\u10e8\u10d8: Clinical Evaluation of the\u00a0Panbio\u2122COVID-19\/ Flu A&B Rapid Panel.\u00a0.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sponsor: Abbott Rapid Diagnostics Jena GmbH, Start: 01.11.2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Kakha Nadaraia \u2013 Principal Investigator (PI) \u00a0 A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study\u00a0to Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (AMUC2023) SPONSOR: […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-402","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=402"}],"version-history":[{"count":4,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/402\/revisions"}],"predecessor-version":[{"id":925,"href":"https:\/\/hcrplatform.com\/index.php?rest_route=\/wp\/v2\/pages\/402\/revisions\/925"}],"wp:attachment":[{"href":"https:\/\/hcrplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}